Novartis Cholesterol Drug Flop Shakes Lp(a) Race for Amgen, Lilly
A Novartis setback in lowering a stubborn heart-risk protein casts doubt on a multibillion-dollar bet shared by Amgen and Eli Lilly.
For years, cardiovascular medicine has chased a deceptively simple hypothesis: if elevated levels of lipoprotein(a), a genetically determined cholesterol-like particle strongly linked to heart attack and stroke risk, can be pharmacologically reduced, patients should live longer and healthier lives. That logic underpins one of the most watched drug races in the pharmaceutical industry — and it just got considerably more complicated.
Novartis became the first major casualty of that race when its Lp(a)-targeting therapy failed to deliver the clinical outcomes the market had anticipated. The setback is not merely a corporate disappointment; it is a scientific signal that forces a harder question about whether reducing Lp(a) levels in the bloodstream actually translates into fewer cardiovascular events, or whether the protein's role is more complex than current models suggest.
Read more Excelsior Energy Sells Two Solar Plants to Enel for $760M →
The fallout lands hardest on Amgen and Eli Lilly, both of which have committed substantial resources to their own Lp(a)-lowering programs. The Novartis failure does not prove their approaches will stumble — drug mechanisms and patient populations differ — but it meaningfully raises the evidentiary bar investors and regulators will now demand before celebrating any positive headline data. The therapeutic category, once treated as a near-certain growth story given the size of the at-risk population, must now be viewed with sharper skepticism.
What makes the Lp(a) space particularly high-stakes is the unmet need that drove the investment in the first place. Unlike LDL cholesterol, which responds to statins, Lp(a) is largely resistant to existing therapies and is estimated to be elevated in roughly one in five people globally. That enormous addressable market justified the race; the Novartis result is a reminder that biological plausibility and clinical proof are not the same thing. Whether Amgen and Lilly can supply that proof remains the defining question for this corner of cardiovascular medicine.
Continue reading at US Top News and Analysis.
